- Risankizumab (Skyrizi®) Demonstrates Significant Improvements in Clinical Remission and Endoscopic Response in Two Phase 3 Induction Studies in Patients with Crohn’s Disease
- Managing Postoperative Crohn’s Disease Made Easy
- Dispatches from the GUILD Conference 2021
- Teduglutide and Short Bowel Syndrome in Children
- How Common are Pediatric Feeding Disorders?
- Risankizumab (Skyrizi®) Demonstrates Significant Improvements in Clinical Remission and Endoscopic Response in Two Phase 3 Induction Studies in Patients with Crohn’s Disease
- Managing Postoperative Crohn’s Disease Made Easy
- Dispatches from the GUILD Conference 2021
- Teduglutide and Short Bowel Syndrome in Children
- How Common are Pediatric Feeding Disorders?
- Risankizumab (Skyrizi®) Demonstrates Significant Improvements in Clinical Remission and Endoscopic Response in Two Phase 3 Induction Studies in Patients with Crohn’s Disease
- Managing Postoperative Crohn’s Disease Made Easy
- Dispatches from the GUILD Conference 2021
- Teduglutide and Short Bowel Syndrome in Children
- How Common are Pediatric Feeding Disorders?

- This event has passed.
North American Neuroendocrine Tumor Society (NANETS) Annual Symposium
October 3, 2019 - October 5, 2019
Learn about the latest in neuroendocrine tumor (NET) diseases treatment and diagnosis. Discuss new diagnostic and therapeutic techniques, optimal multidisciplinary care, and the future of neuroendocrine tumor research.
The schedule includes an allied health track, early career track, tumor boards, oral abstracts, poster sessions, panel discussions.
~ 500 participants